pregnant or lactating women; known allergy or hypersensitivity to the study drug; patients at high risk of bleeding, defined by: previous intracranial hemorrhage, ischemic stroke in the last 3 months, anatomical vascular alteration of the central nervous system known, such as aneurysms or arteriovenous malformations, malignant neoplasm of the central nervous system known, metastatic solid neoplasia, significant closed head or facial trauma in the last 3 months (defined as any trauma that required medical evaluation or hospitalization), known intracranial abnormalities not listed as absolute contraindications (e.g., benign intracranial tumor), bleeding in the last 2 to 4 weeks (excluding menstrual bleeding), surgical procedure in the last 3 weeks, current use of full-dose anticoagulants (warfarin, enoxaparin or new anticoagulants) or dual antiplatelet therapy, thrombocytopenia (<100,000/ml) or international normalized ratio (inr) > 1.3; renal failure, defined as glomerular filtration rate (gfr) estimated by the formulas modification of diet in renal disease (mdrd) or chronic kidney disease epidemiology collaboration (ckd-epi) <30 ml/min/1.73m2; previous participation in the study; history of liver disease (cirrhosis) reported by the patient or in medical records, presence of esophageal varices or presence of ascites; decompensated heart failure, defined by the presence of dyspnea attributed to cardiac cause, edema of the lower limbs, crackles on pulmonary auscultation or pathological jugular turgency. participation in other clinical trials with antivirals in covid-19

pregnant or lactating women; known allergy or hypersensitivity to the study drug; patients at high risk of bleeding, defined by: previous intracranial hemorrhage, ischemic stroke in the last 3 months, anatomical vascular alteration of the central nervous system known, such as aneurysms or arteriovenous malformations, malignant neoplasm of the central nervous system known, metastatic solid neoplasia, significant closed head or facial trauma in the last 3 months (defined as any trauma that required medical evaluation or hospitalization), known intracranial abnormalities not listed as absolute contraindications (e.g., benign intracranial tumor), bleeding in the last 2 to 4 weeks (excluding menstrual bleeding), surgical procedure in the last 3 weeks, current use of full-dose anticoagulants (warfarin, enoxaparin or new anticoagulants) or dual antiplatelet therapy, thrombocytopenia (<100,000/ml) or international normalized ratio (inr) > 1.3; renal failure, defined as glomerular filtration rate (gfr) estimated by the formulas modification of diet in renal disease (mdrd) or chronic kidney disease epidemiology collaboration (ckd-epi) <30 ml/min/1.73m2; previous participation in the study; history of liver disease (cirrhosis) reported by the patient or in medical records, presence of esophageal varices or presence of ascites; decompensated heart failure, defined by the presence of dyspnea attributed to cardiac cause, edema of the lower limbs, crackles on pulmonary auscultation or pathological jugular turgency. participation in other clinical trials with antivirals in covid-19

1. pregnant or lactating women; 2. known allergy or hypersensitivity to the study drug; 3. patients at high risk of bleeding, defined by: 1. previous intracranial hemorrhage, 2. ischemic stroke in the last 3 months, 3. anatomical vascular alteration of the central nervous system known, such as aneurysms or arteriovenous malformations, 4. malignant neoplasm of the central nervous system known, 5. metastatic solid neoplasia, 6. significant closed head or facial trauma in the last 3 months (defined as any trauma that required medical evaluation or hospitalization), 7. known intracranial abnormalities not listed as absolute contraindications (e.g., benign intracranial tumor), 8. bleeding in the last 2 to 4 weeks (excluding menstrual bleeding), 9. surgical procedure in the last 3 weeks, 10. current use of full-dose anticoagulants (warfarin, enoxaparin or new anticoagulants) or dual antiplatelet therapy, 11. thrombocytopenia (<100,000/ml) or international normalized ratio (inr) > 1.3; 4. renal failure, defined as glomerular filtration rate (gfr) estimated by the formulas modification of diet in renal disease (mdrd) or chronic kidney disease epidemiology collaboration (ckd-epi) <30 ml/min/1.73m2; 5. previous participation in the study; 6. history of liver disease (cirrhosis) reported by the patient or in medical records, presence of esophageal varices or presence of ascites; 7. decompensated heart failure, defined by the presence of dyspnea attributed to cardiac cause, edema of the lower limbs, crackles on pulmonary auscultation or pathological jugular turgency. 8. participation in other clinical trials with antivirals in covid-19

1. pregnant or lactating women; 2. known allergy or hypersensitivity to the study drug; 3. patients at high risk of bleeding, defined by: 1. previous intracranial hemorrhage, 2. ischemic stroke in the last 3 months, 3. anatomical vascular alteration of the central nervous system known, such as aneurysms or arteriovenous malformations, 4. malignant neoplasm of the central nervous system known, 5. metastatic solid neoplasia, 6. significant closed head or facial trauma in the last 3 months (defined as any trauma that required medical evaluation or hospitalization), 7. known intracranial abnormalities not listed as absolute contraindications (e.g., benign intracranial tumor), 8. bleeding in the last 2 to 4 weeks (excluding menstrual bleeding), 9. surgical procedure in the last 3 weeks, 10. current use of full-dose anticoagulants (warfarin, enoxaparin or new anticoagulants) or dual antiplatelet therapy, 11. thrombocytopenia (<100,000/ml) or international normalized ratio (inr) > 1.3; 4. renal failure, defined as glomerular filtration rate (gfr) estimated by the formulas modification of diet in renal disease (mdrd) or chronic kidney disease epidemiology collaboration (ckd-epi) <30 ml/min/1.73m2; 5. previous participation in the study; 6. history of liver disease (cirrhosis) reported by the patient or in medical records, presence of esophageal varices or presence of ascites; 7. decompensated heart failure, defined by the presence of dyspnea attributed to cardiac cause, edema of the lower limbs, crackles on pulmonary auscultation or pathological jugular turgency. 8. participation in other clinical trials with antivirals in covid-19

1. pregnant or lactating women; 2. known allergy or hypersensitivity to the study drug; 3. patients at high risk of bleeding, defined by: 1. previous intracranial hemorrhage, 2. ischemic stroke in the last 3 months, 3. anatomical vascular alteration of the central nervous system known, such as aneurysms or arteriovenous malformations, 4. malignant neoplasm of the central nervous system known, 5. metastatic solid neoplasia, 6. significant closed head or facial trauma in the last 3 months (defined as any trauma that required medical evaluation or hospitalization), 7. known intracranial abnormalities not listed as absolute contraindications (e.g., benign intracranial tumor), 8. bleeding in the last 2 to 4 weeks (excluding menstrual bleeding), 9. surgical procedure in the last 3 weeks, 10. current use of full-dose anticoagulants (warfarin, enoxaparin or new anticoagulants) or dual antiplatelet therapy, 11. thrombocytopenia (<100,000/ml) or inr (international standardized ratio) > 1.3; 4. renal failure, defined as glomerular filtration rate (gfr) estimated by the formulas mdrd or ckd-epi <30ml/min/1.73m2; 5. previous participation in the study; 6. history of liver disease (cirrhosis) reported by the patient or in medical records, presence of esophageal varices or presence of ascites; 7. decompensated heart failure, defined by the presence of dyspnea attributed to cardiac cause, edema of the lower limbs, crackles on pulmonary auscultation or pathological jugular turgency. 8. participation in other clinical trials with antivirals in covid-19

1. pregnant or lactating women; 2. known allergy or hypersensitivity to the study drug; 3. patients at high risk of bleeding, defined by: 1. previous intracranial hemorrhage, 2. ischemic stroke in the last 3 months, 3. anatomical vascular alteration of the central nervous system known, such as aneurysms or arteriovenous malformations, 4. malignant neoplasm of the central nervous system known, 5. metastatic solid neoplasia, 6. significant closed head or facial trauma in the last 3 months (defined as any trauma that required medical evaluation or hospitalization), 7. known intracranial abnormalities not listed as absolute contraindications (e.g., benign intracranial tumor), 8. bleeding in the last 2 to 4 weeks (excluding menstrual bleeding), 9. surgical procedure in the last 3 weeks, 10. current use of full-dose anticoagulants (warfarin, enoxaparin or new anticoagulants) or dual antiplatelet therapy, 11. thrombocytopenia (<100,000/ml) or inr (international standardized ratio) > 1.3; 4. renal failure, defined as glomerular filtration rate (gfr) estimated by the formulas mdrd or ckd-epi <30ml/min/1.73m2; 5. previous participation in the study; 6. history of liver disease (cirrhosis) reported by the patient or in medical records, presence of esophageal varices or presence of ascites; 7. decompensated heart failure, defined by the presence of dyspnea attributed to cardiac cause, edema of the lower limbs, crackles on pulmonary auscultation or pathological jugular turgency. 8. participation in other clinical trials with antivirals in covid-19